The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK

Authors:

Ntais D, Batteson R, Hart R, Hemstock M and Lee D.

Publication type:

Conference Proceedings – Poster

Publication Name:

ISPOR Europe 2019

Citation:

Ntais D, Batteson R, Hart R, Hemstock M and Lee D. The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK. ISPOR Europe 2019. Copenhagen, Denmark. 2-6 November 2019. Poster PCN226.

Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies